
Seton Hall Law Professor Jake Elberg and Brown University Professor Erin Fuse Brown
examine the legal and patient-safety risks of direct-to-consumer telehealth and propose
safeguards to protect the physician-patient relationship in a UC Davis Law Review
article.
GLP-1 medications have rapidly reshaped the weight-loss market, fueled by demand,
aggressive advertising and easier access through telehealth. In 2026, 11% of U.S.
adults reported using GLP-1 medications for weight loss, nearly four times the 3%
reported in 2024, according to Gallup. Companies such as Hims & Hers have expanded
access to FDA-approved drugs, including Wegovy and Ozempic, through online platforms
and cash-pay options.
For Elberg, the rapid expansion of the market raises a question that extends beyond
GLP-1s: What happens when the commercial pathway to a prescription becomes intertwined
with the medical decision to prescribe it?
Elberg, who spent 12 years prosecuting corporate health care fraud and corruption
at the U.S. Department of Justice, explores the issue in a recently published article
with Erin C. Fuse Brown, “Direct-to-Prescription Telehealth and the Corporatization
of Medicine.” Brown is a Professor of Health Services, Policy & Practice and the Director
of the Health Policy & Law Lab at the Brown University School of Public Health. The
article is scheduled for publication in UC Davis Law Review in November 2026.
The concern, Elberg and Brown said, is a new model of direct-to-prescription telehealth
that differs from traditional direct-to-consumer pharmaceutical advertising. “This
is a new development because it doesn't say, ‘Talk to your doctor about using these
drugs,’” Elberg said. “It says, ‘Go to this website, and we will provide you with
a doctor.’” That distinction can change the nature of the doctor-patient encounter.
“Everybody involved in that interaction knows the point is to end up with a prescription
for this particular drug,” Elberg said.
In a traditional medical relationship, a prescription is supposed to reflect an independent
judgment about what is best for the patient. But when a physician works within a system
that generates revenue when a prescription is written, Elberg and Brown argue, the
financial incentive can become embedded in the relationship.
The issue is particularly significant as consumers increasingly encounter GLP-1 medications
through physicians, social media, influencers and direct-to-consumer advertising.
Elberg said the concern is not simply that a physician might intentionally act improperly.
Instead, financial incentives can become part of the business structure. “Everybody
involved knows you better be writing these prescriptions or the company isn't going
to work,” he said.
Those concerns are compounded by the limitations of existing law. Elberg and Fuse
Brown examine federal statutes, including the Anti-Kickback Statute and Stark Law,
which are designed in part to prevent inappropriate financial incentives in health
care. But many direct-to-prescription telehealth transactions involve patients paying
out of pocket rather than government health programs. “Existing tools are really not
sufficient to address the concerns about these relationships and this behavior,” Elberg
said.
The authors propose giving state medical boards a stronger role in regulating financially
conflicted prescribing relationships. They also propose a federal statute that would
address the problem directly. The goal is not to restrict telehealth, which Elberg
and Brown see as an important tool for improving access and affordability. Rather,
it is to distinguish patient-centered care from prescription-driven commerce.
“Telehealth as a whole is a wonderful thing because there are real concerns about
access and affordability,” Elberg said. But when telehealth becomes a mechanism for
obtaining a particular product rather than receiving care, the risks change. “The
concern is that folks who are looking to not do the right thing have the ability to
put that on steroids through telehealth.”
For Elberg, the stakes extend beyond the current GLP-1 boom. Without meaningful safeguards,
direct-to-prescription medicine could “proliferate and become the new normal,” with
companies and influencers increasingly marketing medications directly to patients
and steering them toward providers with few prescribing barriers. “That’s going to
really change how medicine works,” Elberg warned. The implications could extend well
beyond weight-loss drugs.
“There’s nothing that would stop a pharmaceutical company from saying, ‘I’m going
to have an influencer convince patients that they need this cholesterol medication
or whatever drug they need for the issue they’re dealing with.’”
Elberg and Brown’s forthcoming article ultimately asks where the line should be drawn
between expanding access to care and allowing commercial interests to shape medical
judgment. As telehealth, pharmaceutical marketing and consumer demand increasingly
converge, that line may help determine not only how patients access medicine, but
how medicine itself is delivered.
Professor Jake Elberg teaches Health Care Fraud & Corruption and serves as faculty director of Seton Hall Law’s Center for Health & Pharmaceutical
Law and its global Health Care Compliance Certificate Programs around the world.
For more information, please contact:
Office of Communications and Marketing
(973) 642-8714
[email protected]




